In a report released on November 14, David Evans from Kepler Capital maintained a Buy rating on Merck KGaA (0O14 – Research Report), ...

The miniature models have the potential to significantly speed up vaccine development, advance cancer treatment research, and enhance health outcomes for a wide range of diseases. To gain deeper ...

Immune cells produced during severe COVID-19 infection may shrink tumors. The unexpected mechanism offers a new therapeutic ...

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Driven by growth across the board, including in its semiconductor business, German science and technology company Merck ...

The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

Merck KGaA on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by temporarily lower spending on drug ...

German sci-tech giant Merck is very optimistic about its prospects in the Chinese market and will continue to strengthen its ...